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The HLA-A*0201-Restricted H-Y Antigen Contains
a Posttranslationally Modified Cysteine That
Significantly Affects T Cell Recognition
Leslie Meadows,*# Wei Wang,²# evoke transplant rejectionor Graft-versus-Host-Disease
(Rotzschke et al., 1990; Goulmy, 1996). The most exten-Joke M. M. den Haan,³# Els Blokland,³
Carla Reinhardus,³ Jan W. Drijfhout,³ sively studied mHag is the male-specific H-Y antigen.
This antigen promotes rejection of male-to-female skinJeffrey Shabanowitz,* Richard Pierce,²
Alexander I. Agulnik,§ Colin E. Bishop,§ grafts in inbred mice strains, whereas transplants made
in the other sex combinations always succeed (EichwaldDonald F. Hunt,‖ Els Goulmy,³
and Victor H. Engelhard² and Silmser, 1955). In humans, the demonstration of H-Y
as a transplantation antigen was based on the observa-*Department of Chemistry
University of Virginia tion of strong posttransplant cytotoxic T lymphocyte
(CTL) responses specific for male donor HLA-matchedCharlottesville, Virginia 22901
²Department of Microbiology target cells in the peripheral blood lymphocytes of a
female patient who rejected the bone marrow transplantand Beirne Carter Center for Immunology Research
University of Virginia of her HLA-identical brother (Goulmy et al., 1976). It
has subsequently been shown that H-Y antigens areCharlottesville, Virginia 22908
³Department of Immunohematology and Bloodbank ubiquitously expressed on cells of hematopoietic and
University Hospital Leiden nonhematopoietic origin (de Bueger et al., 1992b), and
2333 AA Leiden H-Y-specific T cell responses can occur following organ
The Netherlands transplantation, blood transfusions, and bone marrow
§Departments of Obstetrics and Gynecology transplants (Goulmy, 1988).
and Human and Molecular Genetics Identification of the specific MHC-associated pep-
Baylor College of Medicine tides that are recognized by individual T cell epitopes
Houston Texas 77030 has generally been accomplished by using MHC allele±
‖Department of Pathology specific peptide-binding motifs to screen known source
University of Virginia proteins and testing the peptides identified for their abil-
Charlottesville, Virginia 22908 ity to sensitize appropriate target cells for recognition
(reviewed in Engelhard, 1994). However, we have devel-
oped a technique for the identification of such peptides
Summary without prior knowledge of the source protein. By com-
bining microcapillary liquid chromatography/electro-
A peptide recognized by two cytotoxic T cell clones spray ionization mass spectrometry with T cell epitope
specific for the human minor histocompatibility anti- reconstitution assays, we previously identified peptide
gen H-Y and restricted by HLA-A*0201 was identified. antigens recognized by T cells specific for human xeno
This peptide originates from SMCY, as do two other (Henderson et al., 1993) and alloantigens (W. W. et al.,
H-Y epitopes, supporting the importance of this pro- submitted), human melanoma (Cox et al., 1994), a non-
tein as a major source of H-Y determinants in mice sex-linked human mHag (den Haan et al., 1995), as well
and humans. In naturally processed peptides, T cells as antigens expressed on murine tumors (Huang et al.,
only recognize posttranslationally altered forms of this 1996; Dubey et al., submitted) and cells infected with
peptide that have undergone modification of a cyste- Listeria monocytogenes (Gulden et al., 1996). We also
ine residue in the seventh position. One of these modi- identified a peptide that defines a human H-Y epitope
fications involves attachment of a second cysteine for an HLA-B*0702-restricted CTL (Wang et al., 1995).
residue via a disulfide bond. This modification has pro- This 11 residue peptide is derived from SMCY, an evolu-
found effects on T cell recognition and also occurs in tionarily conserved Y-chromosomal protein.
other class I MHC-associated peptides, supporting its An important advantage of the use of this method for
general importance as an immunological determinant. antigen identification is that the structure of the peptide
responsible for the epitope is directly determined rather
than inferred from the primary amino acid sequence
Introduction and predictive motif information. The importance of this
advantage was made clear when it was recently shown
Class I molecules of the major histocompatibility com- that a peptide epitope derived from the tyrosinase pro-
plex (MHC) bind to peptides derived from intracellular tein and recognized by melanoma-reactive CTL differed
pathogens or from proteins expressed in tumor cells from the predicted sequence owing to a posttransla-
and present them on the cell surface to CD81 T cells of tional modification of an asparagine residue to aspartic
the host immune system (Morrison et al., 1986; Moore acid (Skipper et al., 1996). This modification did not
et al., 1988; Townsend and Bodmer, 1989). Class I mole- significantly alter interaction with the MHC molecule,
cules also present peptides that differ between organ but it had a profound effect on T cell recognition.
or bone marrow transplant donor and recipient and can In the present study, we report the identification of
act as minor histocompatibility antigens (mHag) that peptide epitopes that comprise H-Y antigens recog-
nized by HLA-A*0201-restricted specific CTL clones and
that also originate from the SMCY protein. The use of# These authors contributed equally to this work.
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Definition of Epitopes for H-Y-Specific CTL
in Naturally Processed Peptides
To verify that this was indeed the peptide naturally ex-
pressed on the cell surface and recognized by the T
cell, HLA-A*0201 molecules were immunoaffinity puri-
fied from the H-Y1 B lymphoblastoid cell line (B-LCL)
Blk. The associated peptides were extracted in acid and
fractionated by reverse-phase HPLC with heptafluoro-
butyric acid (HFBA) as the organic modifier. Aliquots of
each fraction were assayed for their ability to reconsti-
tute the epitope recognized by 1R35 and R416 after
incubation with the HLA-A*02011, H-Y2 target cell, T2.
Interestingly, while both CTL clones recognized the
same synthetic peptide, FIDSYICQV, they each recog-
nized components in different HPLC fractions of the
naturally processed material. For the R416 clone, a sin-
gle peak of reconstituting activity was observed in frac-
tion 34, while the 1R35 clone recognized two peaks, one
at fractions 35±37 and one at fraction 39 (Figure 2A).
The active fractions for each clone were pooled sepa-
rately and rechromatographed with trifluoroacetic acid
(TFA) as the organic modifier. A single peak of reconsti-
tuting activity was again observed for the R416 cloneFigure 1. Reactivity of the H-Y-Specific, HLA-A*0201-Restricted
CTL Clone 1R35 with Synthetic Peptides Derived from the Sequence at fractions 43 and 44 (Figure 2B), while the 1R35 clone
of SMCY again recognized two separate peaks, one at fractions
Peptides (5 ng/ml) were preincubated with 51Cr-labeled T2 cells for 26 and 27 and one at fractions 48 and 49 (Figure 2C).
30 min at 378C, followed by the addition of 1R35 cells at an E:T of Tandem mass spectrometry was employed to search
12.5:1. for the (M12H)21 ion of FIDSYICQV at m/z 54421 in each
of the biologically active second dimension fractions.
Although collision-activated dissociation (CAD) spectra
direct antigen identification technology has demon- were recorded on several different ions of m/z 54421
strated that these epitopes are posttranslationally modi- in these fractions, none corresponded to FIDSYICQV.
fied. This newly described modification involves attach- These data suggested either that each CTL clone recog-
ment of a second cysteine residue to a cysteine in the nized a different modified form of this peptide or that
primary sequence via a disulfide bond. Data on the reac- the true epitope for either or both CTLs was a naturally
tion pathway leading to this modification suggests that processed peptide with a primary sequence different
cysteinylated cysteine residues in naturally processed from FIDSYICQV. The most likely site for modification
peptides are likely to be quite common. of FIDSYICQV is the sulfhydryl group of the cysteine
residueat position 7. If this modificationcontains a disul-
Results fide bond, it should be susceptible to reduction. Indeed,
when aliquots of each of the biologically active fractions
Definition of Epitopes for H-Y-Specific CTL were treated with dithiothreitol (DTT), a new ion at m/z
Using Synthetic Peptides 54421 appeared in the mass chromatogram (compare
Two previous reports identified the human and murine top panels in Figures 3A and 3B) and was confirmed by
homologs of the Y-chromosomal protein SMCY as the CAD to be the SMCY sequence FIDSYICQV (Figure 4A).
source of peptide epitopes recognized by H-Y-specific
CTL in the context of HLA-B*0702 and H-2Kk, respec-
tively (Scott et al., 1995; Wang et al., 1995). This made The Peptide Epitope Recognized by CTL
Clone R416 Contains a CysteinylatedSMCY the prime target in searching for H-Y epitopes
restricted by other human class I molecules. To this end, Cysteine Residue
In order to identify the parent peptide that gave rise toa computer program (D'Amaro et al., 1995; Drijfhout et
al., 1995) was used to predict and rank peptides from FIDSYICQV upon reduction, mass spectra were searched
for signals that disappeared on treatment with DTT. Inhuman SMCY that would bind to HLA-A*0201. From
this list, twenty-two peptides whose sequences differed second dimension fractions 43 and 44 of Figure 2B, we
found a peptide at m/z 60421 that disappeared uponfrom the corresponding sequences encoded by the
X-chromosomal homolog, SMCX, were synthesized. treatment of the fraction with DTT (compare middle pan-
els of Figures 3A and 3B). The CAD spectrum of thisWhen these peptides were tested for their ability to re-
constitute the epitope for the HLA-A*0201-restricted, peptide (Figure 4B) confirmed the sequence as FIDSY-
ICQV with a cysteinylated cysteine residue in positionH-Y-specific CD81 CTL clone, 1R35, only a single 9
residue peptide, FIDSYICQV, was active (Figure 1). This 7. The HPLC fractions 43 and 44, in which this peptide
was found in the extract of Blk cells, corresponded topeptide was also recognized by the HLA-A*0201-re-
stricted, H-Y-specific CD41 CTL clone R416 (46% lysis at those recognized by CTL clone R416. Adjacent fractions
42 and 45 neither contained this peptide nor showed5 ng/ml peptide and an effector: target ratio [E:T] of 9:1).
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Figure 3. Ion Chromatograms for Recorded m/z 544.5 and 604
Plots of ion abundance versus chromatographic retention time for
peptides in fraction 43 (Figure 2B) before (A) and after (B) treatment
with DTT. Sample preparation and mass spectrometric analysis areFigure 2. Reconstitution of the H-Y Epitope with HPLC-Fraction-
described in Experimental Procedures. After mass spectra wereated Peptides Extracted from HLA-A*0201 Molecules
acquired, a computer search was conducted to determine the abun-Peptides were prepared from HLA-A*02011 H-Y1 Blk cells and frac-
dance of ions in a two mass unit window centered on m/z 544.5 ortionated by reverse-phase HPLC as described in Experimental Pro-
604. Twice the amount of sample was loaded for the ion chromato-cedures. Aliquots of each fraction were preincubated with 51Cr-
gram in (B).labeled T2 cells at 378C for 30 min, followed by addition of the CTL
clone.
(A) First dimension separation of peptides with HFBA as the organic
Effect of Cysteinylation on CTL Recognitionmodifier. The reconstitution assay was performed using 3% of each
and Binding to HLA-A*0201fraction. The R416 clone (closed square) was used at an effector-
One interesting aspect of these results is that the frac-to-target ratio (E:T) of 14:1 and 1R35 (open circle) at an E:T of 16:1.
(B) Fraction 34 from the separation shown in (A), which contained tions that contained epitope reconstituting activity for
reconstituting activity for clone R416, was rechromatographed with R416 did not contain activity for the 1R35 CTL clone,
TFA instead of HFBA as the organic modifier and the gradient de- despite the fact that both clones recognized the syn-
scribed in Experimental Procedures. The R416 clone was used at
thetic FIDSYICQV peptide. In addition, RPMI-1640 con-an E:T of 14:1 to assay the reconstituting activity of 3% of each
tains 0.21 mM cystine, the oxidized form of cysteine, andfraction.
this could participate in a disulfide exchange reaction(C) Active fractions 36and 39 from the separation shown in (A), which
contained reconstituting activity for clone 1R35, were separately leading tocysteinylation of cysteine containing peptides
pooled and rechromatographed with TFA instead of HFBA as the incubated in this medium. Consequently, the ability of
organic modifier and the gradient described in Experimental Proce- RPMI-1640 to mediate peptide cysteinylation and the
dures. The 1R35 clone was used at an E:T of 13:1 to assay the
impact of this modification on epitope recognition byreconstituting activity of 8% of each fraction.
1R35 and R416 were examined. Target cells were pulsed
with varying doses of unmodified and cysteinylated FID-
SYICQV peptide in regular RPMI-1640 medium and thenR416 sensitizing activity. In addition, in extracts of two
other HLA-A*02011, H-Y1 cells, Rp and DM, the same incubated with CTL in the same medium (Figure 5A).
Under these conditions, both forms of the peptide werecysteinylated peptide was found only in HPLC fractions
that showed R416 sensitizing activity (data not shown). recognized similarly by the R416 clone. However, the
unmodified peptide was recognized about 30-fold betterWe conclude that the epitope for the H-Y-specific, HLA-
A*02011 CTL clone R416 is FIDSYICQV, where the Cys than the cysteinylated form by the 1R35 clone. In con-
trast, when target cell incubation with peptide and thehas been modified by the attachment of another Cys
via a disulfide linkage. CTL assay were done in cystine-free medium for the
Immunity
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Figure 4. Mass Spectra
CAD mass spectra of peptide 1087 (A) recorded on (M12H)21 ion at m/z 544 and the peptide 1207 (B) recorded on the (M12H)21 ion at m/z
604. The (y) and (b) ions (Hunt et al., 1986) have been labeled. In (B), Cys* represents a cysteinylated cysteine residue of 222 mass units.
unmodified peptide and in cystine containing medium by using a 100 pM concentration of the cysteinylated
peptide, which is typical of the concentrations requiredfor the cysteinylated peptide, very large differences in
the sensitizing activity of the two peptides became ap- for reconstitution of several other HLA-A*0201-associ-
ated peptide epitopes (Cox et al., 1994; den Haan et al.,parent for both CTL clones (Figure 5B). Half-maximal
target cell lysis by the R416 CTL clone was achieved 1995; Wang et al., 1995). However, a concentration of
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Figure 6. Peptide Binding to HLA-A*0201
HPLC-purified peptides were assayed for their ability to inhibit the
binding of the iodinated peptide FLPSDYFPSV to affinity-purified
HLA-A*0201 molecules in a cell-free peptide-binding assay. Open
squares indicate unmodified FIDSYICQV; closed squares, cysteiny-
lated FIDSYICQV; closed diamonds, IP-30 signal sequence peptide
LLDVPTAAV; and (1), MHN24 alloantigen epitope YLDPAQQNL.
Cysteinylation Is Not an In Vitro Culture Artifact
Despite the fact that the R416 clone showed preferential
Figure 5. H-Y Epitope Reconstitution with Synthetic Peptides
recognition of the cysteinylated form of the peptide, the
In (A), both the unmodified (open symbols) and cystine-treated
demonstration that cysteinylation of peptides can be(closed symbols) FIDSYICQV peptides were tested in RPMI-1640
mediated by RMPI-1640 medium led us to considermedium containing 15% HS. In (B), the unmodified peptide was
whether it was an artifact of in vitro culture of the cellsinitially reduced by incubation of the stock peptide in 2mM DTT
prior to addition to target cells, and the assay was done in cystine- from which the MHC molecules were isolated. In order
free RPMI-1640 (Gibco) containing 1% BSA. The cystine-treated to address this possibility, HLA-A*0201-associated pep-
peptide was tested in RPMI-1640 containing 1% BSA. After preincu- tides were extracted from normal noncultured human
bation of the peptides with 51Cr-labeled T2 cells for 30 min at 378C,
spleen cells. The sensitizing activity for the R416 cloneeither R416 (squares) or 1R35 (circles) was added, and a 4 hr 51Cr
in the spleen cell peptides eluted at the same positionrelease assay was conducted.
on reverse-phase HPLC as did the activity in extracts
of cultured B-LCL (Figure 7). CAD spectra recorded on
180 nM of the unmodified peptide was required to the ions of m/z 60421 in the sensitizing fractions of the
achieve the same result. Conversely, half-maximal tar- spleen cell extract confirmed the presence of the cystei-
get cell lysis by the 1R35 CTL clone was achieved by nylated form of FIDSYICQV (data not shown). This dem-
using a 3 pM concentration of the unmodified peptide, onstrates that cysteinylated MHC-associated peptides
while similar sensitization with the cysteinylated form
required 20nM. These results demonstrate that the 1R35
and R416 clones preferentially recognize the unmodified
and cysteinylated forms of FIDSYICQV, respectively. In
addition, the less disparate recognition of both forms in
normal RPMI-1640 medium containing 0.21 mM cystine
demonstrates that peptide cysteinylation by disulfide
exchange with cystine can occur rapidly under these
conditions.
We also examined whether cysteinylation affected the
ability of the peptide to bind to HLA-A*0201 (Figure 6).
The unmodified FIDSYICQV showed an IC50 value in an
in vitro binding assay with purified HLA-A*0201 of 16
nM, which is indicative of a high affinity interaction.
Interestingly, the cysteinylated form of this peptide
showed an IC50 of 75 nM, demonstrating that this modi-
fication inhibited binding by about 5-fold. Nonetheless, Figure 7. Reconstitution Activity of HPLC-Fractionated Peptides
from HLA-A*02011 Human Spleen Cellsthis IC50 value isstill within the range of values observed
for other peptides that are HLA-A*0201-restricted epi- HLA-A*0201-associated peptides were extracted from affinity-puri-
fied molecules isolated from either noncultured human spleentopes (Figure 6). It is important to note that this differ-
(closed squares)or theB-LCL line Rp (open circles), andfractionatedence in peptide binding is still substantially less than
by reverse-phase HPLC with HFBA as organic modifier. Both prepa-the 3±4 orders of magnitude differences in CTL recogni-
rations were run sequentially on the same column, with the spleen-
tion of the two peptides in cystine-free medium. Thus, derived peptides run first. Aliquots of each fraction corresponding
the major impact of cysteinylation is on the structure of to 2.5 3 109 cell equivalents were incubated with 51Cr-labeled T2
cells and then CTL clone R416.the epitope recognized by each CTL clone.
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are produced in vivo and are not an artifact of in vitro 1994b). Since self-tolerance to SMCX will limit the num-
ber of SMCY peptides that could give rise to H-Y epi-culture.
topes in association with different MHC molecules, it
may seem surprising that there is sufficient polymor-Cysteinylation Occurs in Multiple
phism in this sequence to allow the generation of differ-MHC-Associated Peptides
ent peptides that are both male-specific and capable of
Work related to the identification of naturally processed
binding to different MHC molecules. This is likely to be
epitopes had led to the discovery of two additional HLA-
due to the fact that SMCY is a very large protein (.1500
A*0101-associated peptides that are derivatized by cys-
residues) that differs from the female homolog by over
teinylation. These were initially identified because they
200 residues that are relatively uniformly distributed
contained an unusual residue mass of 222. In each case, throughout its length. These create the potential to gen-
treatment of the sample with DTT converted the 222 Da erate a large number of distinct SMCY-specific peptides
residue mass to that of cysteine, a net change of 119 as H-Y epitopes. It will be interesting to determine
Da. This suggested that the extra mass in the untreated whether the proteins that encode other mHag also share
samples resulted from cysteinylation. To confirm this these characteristics.
hypothesis, synthetic peptides were prepared and An important result of this study is that the peptide
shown to coelute with the naturally occurring material epitope recognized by R416 CTL clone in extracts from
and also to have identical CAD spectra. The two peptide HLA-A*0201 molecules has undergone a posttransla-
sequences are FXDTDTXC*Y and FTESCEXC*Y, where tional modification in which a second cysteine residue
(X) refers to Leu or Ile, two residues of identical mass has been covalently linked to a cysteine in the peptide
that cannot be distinguished on the triple quadrupole sequence via a disulfide bond. This modification aug-
instrument, and (C*) refers to a cysteinylated cysteine ments recognition by R416 by over 1000-fold, despite
residue. In the case of the latter peptide, while the cyste- the fact that it also reduces the binding affinity of the
ine at P5 was not cysteinylated, it was amidocarboxyl- peptide for HLA-A*0201 by about 5-fold. This same mod-
methylated. This modification occurred as a result of ified peptide was also identified as the only active spe-
the inclusion of iodoacetamide as a protease inhibitor cies in HPLC fractions recognized by R416 from 3 differ-
in the buffer used to lyse the B-LCL. This reagent was ent H-Y1, HLA-A*02011 cell lines, as well as in human
not present in the culture medium or in any of the last spleen cells. Taken together, these data clearly define
wash or elution buffers used in affinity purification of the epitope recognized by the CD41 clone, R416, as the
the MHC molecules or the elution of the associated cysteinylated form of FIDSYICQV.
peptides, indicating that this cysteine residue is accessi- The results of epitope reconstitution experiments sug-
ble to this modification while it is bound to the MHC gest that one possible mechanism for cysteine modifica-
molecule. Collectively, these results suggest that cystei- tion of peptides extracted from cultured cells is disulfide
exchange with the 0.21mM cystinepresent in theslightlynylation is likely to be a widespread modification of
basic RPMI-1640 medium. Although this might suggestMHC-associated peptides, but that both modified and
that its occurrence is an artifact of in vitro culture, theunmodified cysteine residues may be present in individ-
presence of the same cysteinylated species in peptidesual peptides.
extracted from freshly isolated human spleen cells ar-
gues against this possibility. Serum also contains up
Discussion to 0.1 mM cystine and has a pH that would support
cysteinylation of any free cysteine residues accessible
In this paper, we have identified a peptide epitope for on thecell surface, so it is possible that thesame mecha-
the H-Y-specific, HLA-A*0201-restricted CTL clone R416 nism of modification could occur in vivo. However, our
and provided partial identification information for a sec- experiments do not rule out the possibility that cysteiny-
ond epitope for the H-Y-specific, HLA-A*0201-restricted lation might occur before or after peptide binding to
CTL clone 1R35. The source of both epitopes appears MHC molecules in the endoplasmic reticulum (ER), since
to be SMCY, which was previously identified as the this compartment contains the components that medi-
source for two other H-Y epitopes restricted by other ate disulfide bond formation and exchange during pro-
murine and human MHC molecules (Scott et al., 1995; tein folding. Regardless of the exact mechanism, these
Wang et al., 1995).SMCY isexpressed inmultiple tissues results suggest that this modified form of the peptide
and maps to the same Yq deletion interval as the human is the epitope that stimulated CTL clone R416 in vivo.
H-Y antigen controlling locus HY (Cantrell et al., 1992; Our results also established that twoother MHC-asso-
O'Reilly et al., 1992). Interestingly, genetic mapping of ciated peptides have undergone cysteinylation of cyste-
the mouse Y chromosome has suggested that at least ine residues in their sequences, but that not every cyste-
two and up to five distinct loci, including SMCY, encode ine residue is modified in this way. If modification occurs
H-Y antigens (King et al., 1994). With a single exception after peptide binding to the MHC molecule, either in the
(Greenfield et al., 1996), all of the epitopes identified to ER or at the cell surface, then it would depend upon
date from both mouse and human have been derived accessibility of the cysteine side chain to aqueous solu-
from the SMCY protein. SMCX, a homolog of the SMCY tion. The ability of an uncysteinylated residue to be de-
protein located on the X chromosome, is 85% identical rivatized by iodoacetamide while it is bound to MHC
to SMCY at the amino acid sequence level. SMCX is molecules suggests that there may be additional con-
ubiquitously expressed by both the active and the inac- straints on cysteinylation, even among accessible resi-
tive X chromosomes in both mice and humans (Agulnik dues. Alternatively, if modification occurs prior to pep-
tide binding to the MHC molecule in the ER, thenet al., 1994a; Agulnik et al., 1994b; Wu et al., 1994a,
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undergone multiple transfusions and who had rejected HLA-identi-cysteinylation may exert a pronounced influence on the
cal male bone marrow (Goulmy et al., 1977; de Bueger et al., 1992a).ability of peptides to bind and, in some cases, might
Both clones recognize H-Y in the context of HLA-A*0201. The clonespreclude binding altogether. In sum, we conclude that
were cultured by weeklystimulation with irradiated allogeneic PBMC
cysteinylation is not rare, but is a highly probable modifi- and EBV-transformed B-LCL in RPMI-1640 medium containing 15%
cation of any free cysteine residues in peptides that human serum, 3 mM L-glutamine, 1% leucoagglutinin, and 20 U/ml
point out of the MHC-binding pocket. recombinant IL-2. Frozen aliquots were thawed and cultured for 1±3
days in RPMI-1640 containing 5±15% human or fetal bovine serumOur results also showed that a second H-Y-specific,
and 20 U/ml recombinant IL-2 before use in cytotoxicity assays. TheHLA-A*0201-restricted CD81 CTL clone, 1R35, preferen-
HLA-A*02011 male B-LCL Blk, DM, and Rp and the HLA-A*02011tially recognizes the unmodified, as opposed to cystei-
antigen-processing mutant cell line T2 were maintained in IMDMnylated, form of the same SMCY-derived peptide. How-
containing 5% FCS or in RPMI-1640 containing 3 mM L-glutamine
ever, this unmodified form of the peptide was not and 10% FCS.
present in cell extracts in any measurable quantity. In-
stead, epitope-reconstituting activity for this CTL clone
Extraction and HPLC Fractionation of
was present in two fractions, neither of which have re- Immunoaffinity-Purified Peptides
tention times that correspond to that of the unmodified HLA-A*0201 molecules were immunoaffinity-purified from 10 3 1010
synthetic peptide. DTT treatment of these two active H-Y1 HLA-A*02011 Blk cells, and the bound peptides were sepa-
rated as described (Hunt et al., 1992; de Bueger et al., 1993; denfractions resulted in the appearance of the unmodified
Haan et al., 1995), except that 1% CHAPS was substituted for NP-peptide. However, we have as yet beenunable to identify
40 in all preparative steps. Peptides were eluted from the HLA-the modified parent species. Nonetheless, these results
A*0201 molecule with 10% acetic acid, 1% TFA and separated fromsuggest that the 1R35 CTL clone is specific for a second
the HLA-A*0201 heavy chain and b2-microglobulin with a 10 kDa
distinct modification of the FIDSYICQV peptide. In this Centricon filter (Amicon). Peptides extracts were fractionated by
regard, a recent report described a modification involv- HPLC on a reverse-phase C2/C18 column (3 mm particles, 120 AÊ pore
ing the addition of an unidentified mass of 102 Da to a size, 2.1 mm inner diameter, 10 cm length), using the Pharmacia
Smart System. For the first dimension, separation buffer A was 0.1%cysteine residue in an HLA-A*0201-associated peptide
HFBA in water, and buffer B was 0.1% HFBA in acetonitrile. Thederived from vinculin (di Marzo Veronese et al., 1996).
gradient was 100% buffer A (0±20 min), 0%±12% buffer B (20±25Further work will be necessary to establish the source,
min), and 12%±50% buffer B (25±80 min) at a flow rate of 100 ml/mechanism, and generality of other modifications of
min, and 100 ml fractions were collected. For second dimension
cysteine residues in class I±associated peptides. separations, TFA was substituted for HFBA. For separation of the
The cysteinylation demonstrated here represents the first dimension fraction that contained epitope activity for the 1R35
second example of a naturally occurring posttransla- clone, the gradient was 100% buffer A (0±29 min), 0%±22% buffer
B (29±34 min), 22% buffer B (34±39 min), and 22%±27.9% buffer Btional modification of class I MHC-associated peptides.
(39±98 min) at a flow rate of 100 ml/min. For separation of the firstWe previously identified a peptide originating from
dimension fraction that contained epitope activity for the R416tyrosinase that was modified by the conversion of an
clone, the gradient was 100% buffer A (0±29 min), 0%±18% bufferasparagine residue to aspartic acid, apparently owing
B (29±34 min), 18% buffer B (34±39 min), and 18%±23.9% buffer B
to N-linked glycosylation and deglycosylation reactions (39±98 min) at a flow rate of 100 ml/min. In both cases, 100 ml
(Skipper et al., 1996). Both of these modifications were fractions were collected.
detected only through the use of mass spectrometry for
peptide sequencing and were not immediately predict- Epitope Reconstitution Assay
able by techniques of antigen identification based on To test for the epitope reconstituting activity of HPLC fractions,
cDNA cloning and peptide-binding motifs (Wolfel et al., aliquots were diluted into 25 ml of Hank's BSS containing 50 mM
HEPES and incubated with 2500 51Cr-labeled T2 cells in 25 ml of1994). In addition, both of these modifications have a
RPMI-1640 containing 3 mM L-glutamine and 15% human serumprofound impact on T cell recognition, while they have
for 30 min at 378C. CTL were then added to give a final volume ofa modest effect of peptide binding to the MHC molecule.
150 ml. After 4 hr at 378C, 51Cr release in the supernatant was mea-Class II MHC±associated peptides have also been
sured by standard methodology. The same methodology was em-
shown to be posttranslationally modified by the attach- ployed for theanalysis of the activity of synthetic peptides. However,
ment of carbohydrate side chains (Chicz et al., 1993; to avoid cysteinylation of peptides during incubation with target
Michaelsson et al., 1994), the extent of which affects T cells and CTL, assays were also performed in cystine-free RPMI-
1640 containing 3 mM L-glutamine and 1% BSA, using peptidescell recognition of the peptides (Michaelsson et al.,
that had been dissolved in Hank's BSS containing 50 mM Hepes1994), and we think it very likely that class II±associated
and 2 mM DTT.peptides will undergo both asparagine residue±to±
aspartic acid conversion and cysteinylation. Collec-
Mass Spectrometrytively, all of these results indicate that the occurrence
Fractions from second dimension HPLC separations that containedof several types of posttranslational modifications of
epitope reconstitution activity were analyzed by microcapillaryMHC-associated peptides is commonplace and that the
HPLC-electrospray ionization mass spectrometry (Hunt et al., 1992).
influence of these modifications must be taken into ac- Peptides were loaded onto a C18 microcapillary column (75 mm
count in attempts topredict immunologically active pep- i.d. 3 10 cm) and eluted directly into the mass spectrometer with
tides from known protein sequences and in the design a gradient of 0%±80% acetonitrile in 0.1% acetic acid over 12 min
at 0.5 ml/min. In some experiments, samples were reduced by load-of peptide-based immunotherapeutics.
ing them onto the microcapillary column and washing them with 5
ml of a 10 mM solution of DTT in ammonium acetate (pH 8.5). MassExperimental Procedures
spectra and CAD mass spectra were recorded on a Finnigan-MAT
TSQ-7000 (San Jose, California) triple quadrupole mass spectrome-Cell Culture
ter equipped with an electrospray ion source. Electrospray ionizationThe CD81 cytotoxic T cell clone 1R35 and the CD41 cytotoxic and
was accomplished with a voltage differential of 4.6 keV on the needleproliferative T cell clone R416 were derived by limiting dilution cul-
ture from the PBMC of a female aplastic anemia patient who had and a sheath liquid consisting of a 70:30 mixture of methanol/ 0.1%
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acetic acid flowing at 1±2 ml/min. Mass spectra were acquired every de Bueger, M., Bakker, A., and Goulmy, E. (1992a). Existence of
mature human CD41 T cells with genuine class I restriction. Eur. J.1.5 s over the range m/z 300±1400.
Immunol. 22, 875±878.
Synthetic Peptides deBueger, M., Rood, J.J., Bakker, A., vanderWoude, F., andGoulmy,
Peptides were synthesized by solid-phase FMOC chemistry and E. (1992b). Tissue distribution of human minor histocompatibility
Wang resins on an AMS 422 multiple peptide synthesizer (Gilson antigens: ubiquitous versus restricted tissue distribution indicates
Medical Electronics, Middletown, WI). Cysteinylation was accom- heterogeneity among human cytotoxic T lymphocyte defined non-
plished by incubating synthetic peptides in a solution of aqueous MHC antigens. J. Immunol. 149, 1788±1794.
ammonium hydroxide containing excess cystine for 5 min at room
de Bueger, M., Verreck, F., Blokland, E., Drijfhout, J.W., Amons, R.,temperature. The reaction was terminated by acidifying the solution
Koning, F., and Goulmy, E. (1993). Isolation of an HLA-A2.1 extractedwith glacial acetic acid. Peptides were purified to greater than 90%
human minor histocompatibility peptide. Eur. J. Immunol. 23,homogeneity by reverse-phase HPLC and characterized by mass
614±618.spectrometry.
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